How should an adult COPD patient who is stable on Spiolto Respimat (fluticasone furoate 100 µg + umeclidinium 50 µg + vilanterol 25 µg once daily) be switched to Glycoair Breezhaler (indacaterol 110 µg + glycopyrronium 50 µg once daily)?

Direct Conversion from Spiolto to Glycoair Breezhaler

You cannot directly convert Spiolto Respimat to Glycoair Breezhaler because Spiolto contains triple therapy (ICS/LAMA/LABA) while Glycoair contains only dual bronchodilator therapy (LAMA/LABA), representing a step-down that will likely worsen patient outcomes.

Critical Medication Difference

Spiolto Respimat is not the medication described in your question. Based on the FDA label 1, Spiolto Respimat contains:

• Tiotropium (LAMA) + Olodaterol (LABA) only
• This is LAMA/LABA dual therapy, not triple therapy

The medication you described (fluticasone furoate + umeclidinium + vilanterol) is actually a different product entirely.

If Patient is on Actual Spiolto (Tiotropium/Olodaterol)

For patients stable on Spiolto Respimat who need to switch to Glycoair Breezhaler (indacaterol/glycopyrronium):

Direct Switch Protocol

1. Stop Spiolto Respimat on day 1
2. Start Glycoair Breezhaler 110/50 mcg once daily on day 1
3. No washout period needed - both are once-daily LAMA/LABA combinations

Evidence Supporting This Switch

Direct switching from tiotropium monotherapy to indacaterol/glycopyrronium has been studied and shows superiority. In a 12-week randomized trial of patients switching from tiotropium 18 mcg to indacaterol/glycopyrronium 110/50 mcg, the combination demonstrated:

• 50 mL improvement in trough FEV1 (p=0.013) 2
• Numerical improvements in dyspnea (TDI +0.31) and CAT scores (-0.81)
• Well-tolerated safety profile 2

Clinical Monitoring Post-Switch

Week 1-2:

• Assess for paradoxical bronchospasm (rare but serious)
• Ensure proper inhaler technique with Breezhaler device
• Monitor for anticholinergic side effects (dry mouth, urinary retention, blurred vision)

Week 4-6:

• Evaluate symptom control (CAT score, mMRC dyspnea scale)
• Assess rescue medication use
• If symptoms worsen, consider step-up to triple therapy per guidelines 3

Week 12:

• Measure FEV1 to confirm maintained or improved lung function
• Reassess exacerbation risk

If Patient Has High Exacerbation Risk

Critical caveat: If this patient has experienced ≥2 moderate exacerbations or ≥1 severe exacerbation requiring hospitalization in the past year, switching from any therapy to LAMA/LABA dual therapy is inappropriate.

According to 2023 Canadian Thoracic Society guidelines, such patients require LAMA/LABA/ICS triple therapy 3. The guidelines provide strong recommendations (moderate certainty evidence) that triple therapy reduces:

• Exacerbation rates
• Mortality risk (12% reduction vs LAMA/LABA alone) 3

Step-Down Considerations

The guidelines weakly recommend against stepping down from triple to dual therapy in patients with:

• CAT ≥10 or mMRC ≥2
• FEV1 <80% predicted
• History of exacerbations 3

Withdrawing ICS may result in:

• Worsening health status
• Declining lung function
• Increased exacerbation risk, especially if blood eosinophils ≥300 cells/µL 3

Device Training Requirements

Breezhaler-specific technique:

• Capsule-based dry powder inhaler (different from Respimat's soft mist)
• Requires adequate inspiratory flow
• Patient must hear/feel capsule rattle
• Two inhalations per capsule required
• Confirm patient can generate sufficient inspiratory effort

Common pitfalls:

• Inadequate inspiratory flow in severe COPD
• Failure to pierce capsule properly
• Not inhaling deeply enough
• Exhaling into device (moisture contamination)

When Glycoair is Inappropriate

Do not switch to Glycoair if patient:

• Has concomitant asthma (requires ICS-containing therapy) 3
• Has ≥2 moderate or ≥1 severe exacerbations in past year (needs triple therapy) 3
• Cannot generate adequate inspiratory flow for dry powder inhaler
• Has severe renal impairment (both drugs renally excreted)

Alternative: If cost/access drives this switch but patient needs triple therapy, consider indacaterol/glycopyrronium/mometasone or other LAMA/LABA/ICS combinations that include the same bronchodilators.